PSEVDOEKSFOLİATİV QLAUKOMANIN MÜALİCƏSİNDƏ LATANOPROSTUN İSTİFADƏSİNİN KLİNİKİ EFFEKTİVLİYİ

Xülasə

SUMMARY

Aim – to assess the clinical effcacy and tolerability of Xalatan (Latanoprost 0,005%) in the treatment of different stages of pseudoexfoliation glaucoma (PEX glaucoma).

Materials and methods
36 patients (62 eyes) with primary diagnosed PEX glaucoma who were prescribed Xalatan once daily were included in this prospective study.

Results
The mean follow-up period was 12 months. Mean baseline IOP was 35,4 ± 2.5 mmHg (27.0 –52 mmHg). The mean reduction of IOP was 10,3 (29%) mmHg at 2 weeks after initiating treatment with Xalatan. In 5 (27,8%), 14 (58,3%) and 19 (96,4%) eyes with early, moderate and advanced glaucoma, respectively, prescription of additional antiglaucomatous drops was needed during follow-up. In 15 (24,2%) eyes IOP could not be controlled medicamentously and antiglaucomatous surgery was required. Local adverse effects of latanoprost were recorded in 2 (16,7%) patients.

Conclusion
Xalatan is clinically effective in the treatment of PEX glaucoma, as it provides 29% reduction from baseline IOP with a low rate of local adverse effects. Success rate of Xalatan monotherapy is 38,7% at 12 months.